News

News

April 2, 2024

Azafaros announces promotion of Dr Anke Arnold-Tugulu to Chief Regulatory Officer

March 12, 2024

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients

January 23, 2024

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium

December 11, 2023

Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

June 8, 2023

Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

March 20, 2023

Azafaros Appoints Chief Operating Officer and Head of Finance

February 27, 2023

Beyond Biotech podcast 35: Rare Disease Day

February 20, 2023

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

January 9, 2023

Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress

January 5, 2023

BREAKING NEWS: Azafaros Receives FDA’s IND Clearance and Fast Track Designation

April 24, 2022

Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

February 14, 2022

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference

February 1, 2022

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorderss

June 10, 2020

Azafaros expands executive management team and operations

February 6, 2020

Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline

July 23, 2018

Azafaros announces promotion of Dr Anke Arnold-Tugulu to Chief Regulatory Officer

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium

Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

Azafaros Appoints Chief Operating Officer and Head of Finance

Beyond Biotech podcast 35: Rare Disease Day

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress

BREAKING NEWS: Azafaros Receives FDA’s IND Clearance and Fast Track Designation

Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference

Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis

Azafaros Announces Multiple Presentations at 18th Annual WORLDSymposium™

Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorderss

Azafaros expands executive management team and operations

Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline

Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders

Need more information? Contact us.

About us

Our science

Links

Contact

Office